NCT00991146View on ClinicalTrials.gov

Efficacy and Safety Study of Canakinumab Administered for 6 Months (24 Weeks) in Japanese Patients With Cryopyrin-associated Periodic Syndromes Followed by an Extension Phase

PHASE3CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

October 31, 2009

Primary Completion Date

February 29, 2012

Study Completion Date

February 29, 2012

Conditions
Cryopyrin-associated Periodic SyndromesFamilial Cold Autoinflammatory SyndromeMuckle-Wells SyndromeNeonatal Onset Multisystem Inflammatory Disease
Interventions
DRUG

canakinumab

canakinumab

Trial Locations (3)

812-8582

Novartis Investigative Site, Fukuoka

236-0004

Novartis Investigative Site, Yokohama

606-8507

Novartis Investigative Site, Kyoto

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY